Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: A case series

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3949-3952

  Culine, Stéphane ^a   Sellam, Zineb ^a   Bouaita, Linda ^a   Assaf, Elias ^a   Delbaldo, Catherine ^a   Verlinde Carvalho, Muriel ^a   Pouessel, Damien ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Case series; Lapatinib; Paclitaxel; Salvage therapy; Transitional cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; LOPERAMIDE; METHOTREXATE; PACLITAXEL; VINBLASTINE; VINFLUNINE;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE OVEREXPRESSION; HUMAN; LIVER METASTASIS; METASTASIS; METASTATIC TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SALVAGE THERAPY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; QUINAZOLINES; SALVAGE THERAPY; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84866987918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomised trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608, 2005.
2. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S and von der Maase H: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27: 4454-4460, 2009.
3. Joly F, Houédé N, Noal S, Joly F, Houédé N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, Rolland F, Fléchon A, Henry-Amar M and Culine S: Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer 7: E28-E33, 2009.
4. Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F and El-Hariry IA: A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115: 2881-2890, 2009.
5. McHugh LA, Sayan AE, Mejlvang J, Griffiths TR, Sun Y, Manson MM, Tulchinsky E, Mellon JK and Kriajevska M: Lapatinib, a dual inhibitor of ERBB-1/2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 34: 1155-1163, 2009.
6. Burris HA III, Hurwitz HI, Dees EC, Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S and Spector NL: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305-5313, 2005.
7. Crown JP, Burris HA 3rd, Boyle F, Jones S, Koehler M, Newstat BO, Parikh R, Oliva C, Preston A, Byrne J and Chan S: Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 112: 317-325, 2008.
8. Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E and Hudis C: Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 28: 2982-2988, 2010.
9. Chow NH, Chan SH, Tzai TS, Ho CL and Liu HS: Expression profiles of ERBB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7: 1957-1962, 2001.
10. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B and Dinney CP: Distinctive expression pattern of ERBB family receptors signifies an aggressive variant of bladder cancer. J Urol 179: 353-358, 2008.
11. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM and Davies BR: Evaluation of the therapeutic potential of the epidermal growth factor tyrosine kinase inhibitor gefitinib in preclinical models of bladder Cancer. Clin Cancer Res 10: 4874-4884, 2004.
12. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R and Dinney CP: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257-265, 1999.
13. Philips GK, Halabi S, Sanford BL, Bajorin D and Small EJ: A phase II trial of cisplatin, gemcitabine and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 20: 1074-1079, 2009.
14. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr., Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M and Crawford ED: Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 105: 317-321, 2009.
15. Jacobs MA, Wotkowicz C, Baumgart ED, Neto BS, Rieger-Christ KM, Bernier T, Cohen MS, Libertino JA and Summerhayes IC: Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib. J Urol 178: 1510-1514, 2007.
16. Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P and Vieillefond A: Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann Oncol 21: 815-819, 2010.